Nuclease-resistant synthetic drug-DNA adducts: programmable drug-DNA conjugation for targeted anticancer drug delivery
Source abstract
Abstract
Targeted drug delivery is poised to improve cancer therapy, for which synthetic DNA can serve as targeting ligands (for example, aptamers) or drug nanocarriers. Inspired by natural DNA adducts, we report synthetic drug-DNA adducts (DDAs) for targeted anticancer drug delivery. Multiple copies of anthracycline drugs were site specifically (on deoxyguanosine) conjugated on each DNA, enabling programmable design of DNA and drugs for DDA preparation. DDAs were nuclease-resistant and stable for storage, yet gradually released drugs at physiological temperature. DDAs maintained DNA functionalities, including hybridization-mediated DNA nanoadduct formation and aptamer-mediated target recognition and targeted drug delivery into cancer cells. In a tumor xenograft mouse model, doxorubicin-aptamer adducts significantly inhibited target tumor growth while reducing the side effects. Using histopathological analysis and in situ immunohistochemical analysis of caspase-3 cleavage in mouse tumor and heart, DDAs were confirmed to have a potent antitumor efficacy while reducing tissue deformation and apoptosis in the heart, thus providing a new therapeutic avenue to prevent cardiomyopathy, the most dangerous side effect of doxorubicin leading to heart failure. Overall, DDAs are promising for scale-up production and clinical application in targeted anticancer drug delivery. Drug–DNA adducts have been developed for targeted drug delivery to inhibit tumor growth in mice while reducing side effects. Inspired by natural DNA adducts, researchers in China and USA have developed a simple but programmable way of producing synthetic drug-DNA adducts for targeted cancer therapy. They conjugated multiple copies of anthracycline drugs on each DNA base, using a one-step reaction in physiological buffer. The resultant DNA–drug adducts maintained the capability of DNA backbone to form specific aptamer conformations or to form DNA nanostructures by hybridization. Experiments on mice involving a commonly used chemotherapy drug revealed that the use of the adducts reduces toxicity in the heart, lowering the probability of cardiomyopathy, a frequently lethal side effect of chemotherapy. Drug–DNA adducts are promising for scale-up production and clinical applications of targeted drug delivery. We report nature-inspired drug-DNA adducts (DDAs) as a simple yet programmable platform for site-specific drug-DNA conjugation and application in targeted anticancer drug delivery. With multiple copies of drugs conjugated on one DNA, the DDAs were nuclease-resistant and stable for storage, yet gradually released drugs at physiological temperature. Designer DDAs were able to form nanoadducts by hybridization and fold into drug-aptamer adducts (DAAs) for specific recognition of cancer cells and targeted anticancer drug delivery. In a tumor xenograft mouse model, DAAs significantly inhibited tumor growth and reduced side effects, as verified by tissue analysis of tumors and hearts.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · DNA and Nucleic Acid Chemistry
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (40)
Show source-provided references
1. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 56, 185–229 (2004).10.1124/pr.56.2.6 ↗
2. Chatterjee, K., Zhang, J., Honbo, N. & Karliner, J. S. Doxorubicin cardiomyopathy. Cardiology 115, 155–162 (2010).10.1159/000265166 ↗
3. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R. & Langer, R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2, 751–760 (2007).10.1038/nnano.2007.387 ↗
4. Li, X., Fang, T. & Boons, G.-J. Preparation of well-defined antibody–drug conjugates through glycan remodeling and strain-promoted azide–alkyne cycloadditions. Angew. Chem. Int. Ed. Engl. 126, 7307–7310 (2014).10.1002/ange.201402606 ↗
5. Santra, S., Kaittanis, C., Santiesteban, O. J. & Perez, J. M. Cell-specific, activatable, and theranostic prodrug for dual-targeted cancer imaging and therapy. J. Am. Chem. Soc. 133, 16680–16688 (2011).10.1021/ja207463b ↗
6. Allen, T. M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2, 750–763 (2002).10.1038/nrc903 ↗
7. Cao, Z., Tong, R., Mishra, A., Xu, W., Wong, G. C. L., Cheng, J. & Lu, Y. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew. Chem. Int. Ed. Engl. 48, 6494–6498 (2009).10.1002/anie.200901452 ↗
8. Wang, F., Wang, Y.-C., Dou, S., Xiong, M.-H., Sun, T.-M. & Wang, J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 5, 3679–3692 (2011).10.1021/nn200007z ↗
9. Lo, P. K., Karam, P., Aldaye, F. A., McLaughlin, C. K., Hamblin, G. D., Cosa, G. & Sleiman, H. F. Loading and selective release of cargo in DNA nanotubes with longitudinal variation. Nat. Chem. 2, 319–328 (2010).10.1038/nchem.575 ↗
10. Jiang, Q., Song, C., Nangreave, J., Liu, X., Lin, L., Qiu, D., Wang, Z.-G., Zou, G., Liang, X., Yan, H. & Ding, B. DNA origami as a carrier for circumvention of drug resistance. J. Am. Chem. Soc. 134, 13396–13403 (2012).10.1021/ja304263n ↗
11. Chang, M., Yang, C.-S. & Huang, D.-M. Aptamer-conjugated dna icosahedral nanoparticles as a carrier of doxorubicin for cancer therapy. ACS Nano 5, 6156–6163 (2011).10.1021/nn200693a ↗
12. Lee, H., Lytton-Jean, A. K. R., Chen, Y., Love, K. T., Park, A. I., Karagiannis, E. D., Sehgal, A., Querbes, W., Zurenko, C. S., Jayaraman, M., Peng, C. G., Charisse, K., Borodovsky, A., Manoharan, M., Donahoe, J. S., Truelove, J., Nahrendorf, M., Langer, R. & Anderson, D. G. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389–393 (2012).10.1038/nnano.2012.73 ↗
13. Zhu, G., Zheng, J., Song, E., Donovan, M., Zhang, K., Liu, C. & Tan, W. Self-assembled, aptamer-tethered DNA nanotrains for targeted transport of molecular drugs in cancer theranostics. Proc. Natl Acad. Sci. USA 110, 7998–8003 (2013).10.1073/pnas.1220817110 ↗
14. Zhu, G., Hu, R., Zhao, Z., Chen, Z., Zhang, X. & Tan, W. Noncanonical self-assembly of multifunctional DNA nanoflowers for biomedical applications. J. Am. Chem. Soc. 135, 16438–16445 (2013).10.1021/ja406115e ↗
15. Zhu, G., Meng, L., Ye, M., Yang, L., Sefah, K., O'Donoghue, M. B., Chen, Y., Xiong, X., Huang, J., Song, E. & Tan, W. Self-assembled aptamer-based drug carriers for bispecific cytotoxicity to cancer cells. Chem. Asian J. 7, 1630–1636 (2012).10.1002/asia.201101060 ↗
16. Wu, C., Han, D., Chen, T., Peng, L., Zhu, G., You, M., Qiu, L., Sefah, K., Zhang, X. & Tan, W. Building a multifunctional aptamer-based dna nanoassembly for targeted cancer therapy. J. Am. Chem. Soc. 135, 18644–18650 (2013).10.1021/ja4094617 ↗
17. Wang, K., You, M., Chen, Y., Han, D., Zhu, Z., Huang, J., Williams, K., Yang, C. J. & Tan, W. Self-assembly of a bifunctional dna carrier for drug delivery. Angew. Chem. Int. Ed. Engl. 50, 6098–6101 (2011).10.1002/anie.201008053 ↗
18. Bagalkot, V., Farokhzad, O. C., Langer, R. & Jon, S. An aptamer–doxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew. Chem. Int. Ed. Engl. 45, 8149–8152 (2006).10.1002/anie.200602251 ↗
19. Meng, L., Yang, L., Zhao, X., Zhang, L., Zhu, H., Liu, C. & Tan, W. Targeted delivery of chemotherapy agents using a liver cancer-specific aptamer. Plos ONE 7, e33434 (2012).10.1371/journal.pone.0033434 ↗
20. Kortylewski, M., Swiderski, P., Herrmann, A., Wang, L., Kowolik, C., Kujawski, M., Lee, H., Scuto, A., Liu, Y., Yang, C., Deng, J., Soifer, H. S., Raubitschek, A., Forman, S., Rossi, J. J., Pardoll, D. M., Jove, R. & Yu, H. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27, 925–932 (2009).10.1038/nbt.1564 ↗
21. Weiner, G. J., Liu, H.-M., Wooldridge, J. E., Dahle, C. E. & Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl Acad. Sci. USA 94, 10833–10837 (1997).10.1073/pnas.94.20.10833 ↗
22. Ellington, A. D. & Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818–822 (1990).10.1038/346818a0 ↗
23. Tuerk, C. & Gold, L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505–510 (1990).10.1126/science.2200121 ↗
24. Keefe, A. D., Pai, S. & Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov. 9, 537–550 (2010).10.1038/nrd3141 ↗
25. Zhu, G., Ye, M., Donovan, M. J., Song, E., Zhao, Z. & Tan, W. Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem. Commun. 48, 10472–10480 (2012).10.1039/c2cc35042d ↗
26. Shangguan, D., Li, Y., Tang, Z., Cao, Z., Chen, H. W., Mallikaratchy, P., Sefah, K., Yang, C. J. & Tan, W. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc. Natl Acad. Sci. USA 103, 11838–11843 (2006).10.1073/pnas.0602615103 ↗
27. Sefah, K., Tang, Z., Shangguan, D., Chen, H., Lopez-Colon, D., Li, Y., Parekh, P., Martin, J., Meng, L., Phillips, J. A., Kim, Y. & Tan, W. Molecular recognition of acute myeloid leukemia using aptamers. Leukemia 23, 235–244 (2009).10.1038/leu.2008.335 ↗
28. Tang, Z., Shangguan, D., Wang, K., Shi, H., Sefah, K., Mallikaratchy, P., Chen, H. W., Li, Y. & Tan, W. Selection of aptamers for molecular recognition and characterization of cancer cells. Anal. Chem. 79, 4900–4907 (2007).10.1021/ac070189y ↗
29. Alama, A., Barbieri, F., Cagnoli, M. & Schettini, G. Antisense oligonucleotides as therapeutic agents. Pharmacol. Res. 36, 171–178 (1997).10.1006/phrs.1997.0227 ↗
30. Huang, Y.-F., Shangguan, D., Liu, H., Phillips, J. A., Zhang, X., Chen, Y. & Tan, W. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 10, 862–868 (2009).10.1002/cbic.200800805 ↗
31. Wang, R., Zhu, G., Mei, L., Xie, Y., Ma, H., Ye, M., Qing, F.-L. & Tan, W. Automated modular synthesis of aptamer–drug conjugates for targeted drug delivery. J. Am. Chem. Soc. 136, 2731–2734 (2014).10.1021/ja4117395 ↗
32. Wilson, C. & Keefe, A. D. Building oligonucleotide therapeutics using non-natural chemistries. Curr. Opin. Chem. Biol. 10, 607–614 (2006).10.1016/j.cbpa.2006.10.001 ↗
33. Rosi, N. L., Giljohann, D. A., Thaxton, C. S., Lytton-Jean, A. K. R., Han, M. S. & Mirkin, C. A. Oligonucleotide-modified gold nanoparticles for intracellular gene regulation. Science 312, 1027–1030 (2006).10.1126/science.1125559 ↗
34. van Rosmalen, A., Cullinane, C., Cutts, S. M. & Phillips, D. R. Stability of adriamycin-induced DNA adducts and interstrand crosslinks. Nucleic Acids Res. 23, 42–50 (1995).10.1093/nar/23.1.42 ↗
35. Cutts, S. M. & Phillips, D. R. Use of oligonucletides to define the site of interstand cross-links induced by Adriamycin. Nucleic Acids Res. 23, 2450–2456 (1995).10.1093/nar/23.13.2450 ↗
36. Zeman, S. M., Phillips, D. R. & Crothers, D. M. Characterization of covalent Adriamycin-DNA adducts. Proc. Natl Acad. Sci. USA 95, 11561–11565 (1998).10.1073/pnas.95.20.11561 ↗
37. Swift, L. P., Rephaeli, A., Nudelman, A., Phillips, D. R. & Cutts, S. M. Doxorubicin-DNA adducts induce a non-topoisomerase II–mediated form of cell death. Cancer Res. 66, 4863–4871 (2006).10.1158/0008-5472.CAN-05-3410 ↗
38. Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., Munday, N. A., Raju, S. M., Smulson, M. E., Yamin, T.-T., Yu, V. L. & Miller, D. K. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37–43 (1995).10.1038/376037a0 ↗
39. Shangguan, D., Cao, Z., Meng, L., Mallikaratchy, P., Sefah, K., Wang, H., Li, Y. & Tan, W. Cell-specific aptamer probes for membrane protein elucidation in cancer cells. J. Proteo. Res 7, 2133–2139 (2008).10.1021/pr700894d ↗
40. Heinlein, T., Knemeyer, J.-P., Piestert, O. & Sauer, M. Photoinduced electron transfer between fluorescent dyes and guanosine residues in DNA-hairpins. J. Phy. Chem. B 107, 7957–7964 (2003).10.1021/jp0348068 ↗